Zachary Bessette

Zachary Bessette

Articles by Zachary Bessette

Zachary BessetteCRPC | December 6, 2023
ASCO has provided a rapid update on its guideline recommendations for 177Lutetium-PSMA-617 in mCRPC.
Read More
Zachary BessetteAdvanced Urothelial Carcinoma | December 5, 2023
A recent combined analysis of 2 phase 2 studies indicates that disitamab vedotin has a promising efficacy and safety profile.
Zachary BessetteAdvanced Urothelial Carcinoma | December 5, 2023
The FDA is granting a priority review for EV/pembro as well as nivo/chemo for the treatment of patients with la/mUC.
Zachary BessetteSUO 2023 | November 30, 2023
Drs. Woldu and Pierorazio presented on disparities in RCC care and outcomes as well as appropriate AS in small renal masses.
Zachary BessetteSUO 2023 | November 29, 2023
Dr. McKiernan provided the argument for surveillance in the event of complete clinical response after NAC for MIBC.
Zachary BessetteSUO 2023 | November 29, 2023
Drs. Pierorazio and Eggener moderated a session on simultaneous optimization of organ transplant and GU cancer outcomes.
Zachary BessetteSUO 2023 | November 27, 2023
R-RPLND may offer lower morbidity and improved perioperative outcomes than O-RPLND for patients with CS II testicular cancer.
Zachary BessetteSUO 2023 | November 27, 2023
An analysis compared the outcomes of patients with mRCC who underwent cytoreductive nephrectomy and first-line TKI or IO.
Zachary BessetteSUO 2023 | November 22, 2023
Surgery for locally advanced RCC may be safe for patients after neoadjuvant durvalumab with or without tremelimumab.
Zachary BessetteSUO 2023 | November 22, 2023
New research sheds light on the safety of (177Lu)–PSMA-617 for patients with mCRPC and poor bone marrow reserve.
Zachary BessetteSUO 2023 | November 21, 2023
A poster reported on AEs occurring after Lu-PSMA treatment, as well as variables associated with ER visits.
Zachary BessetteSUO 2023 | November 27, 2023
Recent data suggest good quality of life outcomes for patients with muscle-invasive bladder cancer after trimodality therapy.
Zachary BessetteSUO 2023 | November 27, 2023
A study demonstrated evidence for the clinical utility of blood-based liquid biopsy biomarkers for patients with UTUC.
Zachary BessetteLocalized | November 17, 2023
The FDA approved enzalutamide as the first AR-signaling inhibitor for the treatment of nmCSPC with high-risk BCR.
Zachary Bessette2023 IKCS: North America | November 10, 2023
A Danish study suggests that diabetes has a significant impact on OS in patients with RCC who undergo nephrectomy.
Zachary Bessette2023 IKCS: North America | November 10, 2023
A Merit Award-winning abstract offered insight into differences in RCC susceptibility and implications for genetic screening.
Zachary Bessette2023 IKCS: North America | November 10, 2023
Zanzalintinib shows promising antitumor activity and manageable toxicity in patients with previously treated advanced ccRCC.
Zachary BessetteAdvanced Imaging | November 7, 2023
Clarity announced that 50 patients have now been imaged with 64Cu-SAR-Bombesin in its US-based diagnostic trial.
Zachary BessetteAdvanced Urothelial Carcinoma | November 1, 2023
Lenvatinib plus pembrolizumab versus pembrolizumab alone as a first-line therapy for patients with advanced UC.
Zachary BessetteAdvanced Imaging | October 30, 2023
Clarity Pharmaceuticals has partnered with PSI CRO AG to launch a phase 3 diagnostic trial of SAR-bisPSMA in prostate cancer.